In summary, we found that HR genetic polymorphisms, particularly RAD51 −135G>C, may influence the overall survival and risk of radiation pneumonitis in NSCLC patients treated with definitive radio(chemo)therapy. This evidence concerns the gene RAD51 and radiation pneumonitis.